Advanced Biomed Inc. Financials
This page shows Advanced Biomed Inc. (ADVB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Advanced Biomed Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Advanced Biomed Inc. generates $1.79 in operating cash flow (-$5.8M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Advanced Biomed Inc. generated -$5.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 166.2% from the prior year.
Advanced Biomed Inc. reported -$3.3M in net income in fiscal year 2025. This represents a decrease of 17.1% from the prior year.
Advanced Biomed Inc. earned $-0.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 14.3% from the prior year.
Advanced Biomed Inc. held $2.9M in cash against $0 in long-term debt as of fiscal year 2025.
Advanced Biomed Inc. had 22M shares outstanding in fiscal year 2025. This represents an increase of 8.2% from the prior year.
Advanced Biomed Inc. invested $910K in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Advanced Biomed Inc. invested $32K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 57.3% from the prior year.
ADVB Income Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $186K0.0% | $186K-21.0% | $236K-5.8% | $250K+17.9% | $212K+16.9% | $182K-42.0% | $314K+66.4% | $188K |
| SG&A Expenses | $210K0.0% | $210K-27.0% | $288K-43.8% | $512K+657.1% | $68K-80.0% | $338K-21.7% | $432K-6.7% | $463K |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $2 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $6.9M0.0% | $6.9M+1872.5% | -$387K+72.0% | -$1.4M-52.4% | -$908K-241.9% | -$266K+74.9% | -$1.1M-626.7% | -$145K |
| EPS (Diluted) | $0.310.0% | $0.31+1650.0% | $-0.02+71.4% | $-0.07-40.0% | $-0.05 | $-0.01+80.0% | $-0.05-400.0% | $-0.01 |
ADVB Balance Sheet
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.9M0.0% | $10.9M+73.8% | $6.2M-24.7% | $8.3M+84.0% | $4.5M | N/A | N/A | N/A |
| Current Assets | $10.7M0.0% | $10.7M+83.6% | $5.8M-24.4% | $7.7M+146.3% | $3.1M | N/A | N/A | N/A |
| Cash & Equivalents | $2.6M0.0% | $2.6M-2.0% | $2.7M-48.8% | $5.2M+95.8% | $2.6M0.0% | $2.6M-0.6% | $2.7M-4.1% | $2.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.4M0.0% | $1.4M-57.7% | $3.2M-22.1% | $4.2M+7.0% | $3.9M | N/A | N/A | N/A |
| Current Liabilities | $1.3M0.0% | $1.3M-58.8% | $3.0M-26.0% | $4.1M+7.4% | $3.8M | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.5M0.0% | $9.5M+215.6% | $3.0M-27.3% | $4.1M+567.1% | $619K-43.4% | $1.1M+319.7% | -$498K-352.9% | $197K |
| Retained Earnings | $12.8M+200.0% | -$12.8M+35.0% | -$19.6M-5.9% | -$18.5M-8.1% | -$17.1M | N/A | N/A | N/A |
ADVB Cash Flow Statement
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1M+318.8% | -$514K+15.9% | -$610K+82.1% | -$3.4M-305.0% | -$842K-2736.4% | -$30K+97.2% | -$1.1M | N/A |
| Capital Expenditures | $15K+13.7% | $13K+628.7% | $2K-20.0% | $2K+120.7% | -$11K-153.5% | $20K+174.8% | -$27K | N/A |
| Free Cash Flow | $1.1M+310.7% | -$526K+14.0% | -$612K+82.1% | -$3.4M-300.2% | -$853K-1616.8% | -$50K+95.5% | -$1.1M | N/A |
| Investing Cash Flow | $15K+213.7% | -$13K-628.7% | -$2K+20.0% | -$2K-120.7% | $11K+153.5% | -$20K-174.8% | $27K | N/A |
| Financing Cash Flow | $763K+141.8% | $315K-29.5% | $447K-92.4% | $5.9M+1344.8% | $408K+4.0% | $393K-30.2% | $562K | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ADVB Financial Ratios
| Metric | Q2'26 | Q2'25 | Q1'25 | Q3'25 | Q2'24 | Q1'24 | Q3'24 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | 72.3%0.0pp | 72.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 63.2%0.0pp | 63.2%+69.4pp | -6.2%+10.5pp | -16.7%+3.5pp | -20.2% | N/A | N/A | N/A |
| Current Ratio | 8.560.0 | 8.56+6.6 | 1.92+0.0 | 1.88+1.1 | 0.82 | N/A | N/A | N/A |
| Debt-to-Equity | 0.140.0 | 0.14-0.9 | 1.08+0.1 | 1.01-5.3 | 6.28 | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Advanced Biomed Inc. profitable?
No, Advanced Biomed Inc. (ADVB) reported a net income of -$3.3M in fiscal year 2025.
What is Advanced Biomed Inc.'s earnings per share (EPS)?
Advanced Biomed Inc. (ADVB) reported diluted earnings per share of $-0.16 for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Advanced Biomed Inc.'s free cash flow?
Advanced Biomed Inc. (ADVB) generated -$5.9M in free cash flow during fiscal year 2025. This represents a -166.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Advanced Biomed Inc.'s operating cash flow?
Advanced Biomed Inc. (ADVB) generated -$5.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Advanced Biomed Inc.'s total assets?
Advanced Biomed Inc. (ADVB) had $13.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Advanced Biomed Inc.'s capital expenditures?
Advanced Biomed Inc. (ADVB) invested $32K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Advanced Biomed Inc. spend on research and development?
Advanced Biomed Inc. (ADVB) invested $910K in research and development during fiscal year 2025.
How many shares does Advanced Biomed Inc. have outstanding?
Advanced Biomed Inc. (ADVB) had 22M shares outstanding as of fiscal year 2025.
What is Advanced Biomed Inc.'s current ratio?
Advanced Biomed Inc. (ADVB) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is Advanced Biomed Inc.'s debt-to-equity ratio?
Advanced Biomed Inc. (ADVB) had a debt-to-equity ratio of 2.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Advanced Biomed Inc.'s return on assets (ROA)?
Advanced Biomed Inc. (ADVB) had a return on assets of -23.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Advanced Biomed Inc.'s cash runway?
Based on fiscal year 2025 data, Advanced Biomed Inc. (ADVB) had $2.9M in cash against an annual operating cash burn of $5.8M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Advanced Biomed Inc.'s Piotroski F-Score?
Advanced Biomed Inc. (ADVB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Advanced Biomed Inc.'s earnings high quality?
Advanced Biomed Inc. (ADVB) has an earnings quality ratio of 1.79x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.